SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as traders assess market volatility amidst concerns about regional banks and the potential for a trade war with China. Community discussions revolve around potential support levels and whether the market will experience a significant downturn or a bounce. Increasing VIX levels and rising gold prices add to the uncertain outlook, with some participants bracing for a potential market correction.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending downwards as the community debates whether it's a scam or a buying opportunity, with some pointing to the CEO's past sale of shares as a negative signal. Discussions include potential price targets, upcoming earnings, and the overall valuation of the quantum computing sector. Bears anticipate a significant drop, while bulls hope for a rebound, contributing to the stock's volatility.

ZenaTech, Inc. is an enterprise software technology company, which specializes in mission-critical cloud-based applications integrated with smart hardware to deliver solutions across diverse industries. The firm also develops drone manufacturing, sales, and distribution business. The company was founded by Shaun A. Passley on August 31, 2017 and is headquartered in Vancouver, Canada.

ZenaTech Inc.

ZenaTech is trending due to its plans for congressional meetings to promote drone technology and US manufacturing, sparking community interest in its potential impact on securing funding and shaping policy. Community members are discussing the company's strong management, vision, and possible comparison to Droneshield's growth, while highlighting the increasing US government spending on defense drone contracts. The company's focus on AI drones in the growing defense sector is also a key talking point.

Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada.

Bitfarms Ltd.

Bitfarms (BITF) is trending due to a recently announced offering of convertible senior notes, initially $300M then increased to $500M, intended to fund corporate needs and hedge against share dilution. While some investors express concerns about potential dilution and management decisions, others view the capital raise as a strategic move to fund expansion into AI and high-performance computing (HPC). The community is actively debating the offering's terms, potential impact, and the company's long-term prospects in the crypto mining and AI sectors.

SharpLink Gaming, Inc. is an online performance-based marketing company, which engages in the provision of online platform facilitating sports betting. It connects sports fans, leagues, and sports websites to relevant and timely sports betting content. The company was founded by Robert Phythian in 2019 and is headquartered in Minneapolis, MN.

SharpLink Gaming Inc.

SharpLink Gaming Ltd

SBET is trending due to a recently priced share offering at a premium, signaling institutional confidence and sparking community discussion about the company's Ethereum strategy. Some investors are excited about the potential for future gains as the company continues to accumulate ETH, while others express concerns about dilution and management's performance relative to peers like BMNR. The stock's movements are closely tied to Ethereum's price, making it a subject of debate as crypto markets experience volatility.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending amid discussions about potential acquisitions and expansion plans, including a possible move into stablecoins and new crypto listings; the community is analyzing technical patterns and speculating on future price movements, while also keeping an eye on Bitcoin's influence and overall market conditions.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as investors discuss the company's shift towards AI cloud infrastructure and a recently closed $1 billion convertible notes offering. Community members are weighing the potential impact of this transition and the large capital infusion on IREN's growth prospects, while others debate whether the stock is overvalued. Bullish sentiment remains, with many anticipating significant gains and increased institutional interest.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is seeing increased volatility as traders weigh geopolitical concerns, banking sector jitters, and potential impacts from upcoming economic reports. Community members are actively discussing potential downside risks and hedging strategies, while also debating whether the current market dip presents a buying opportunity or signals a larger correction.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels ($UUUU) is trending amidst discussions about its positioning in the rare earth element (REE) sector and potential government interest. Community members are weighing perspectives on the stock's valuation, recent price action, and the potential impact of U.S.-China trade dynamics on the REE market. The company's uranium assets and production capabilities are also being considered as factors influencing its future performance.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is trending as investors discuss gold's safe-haven appeal amid dollar concerns and potential bond market issues. The community is debating whether the rally is sustainable, with some predicting further gains while others foresee a significant correction. Broader economic factors, including U.S.-China trade dynamics and potential Federal Reserve actions, are also fueling the conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering

Esperion's stock sinks after pricing its common stock offering at $2.50 per share, a 19% discount to the prior close.

Shares of Esperion Therapeutics tumbled almost 20% in premarket trading on Wednesday after the cholesterol drugmaker moved to raise fresh capital through a steeply discounted stock sale.The company priced its new offering at $2.50 per share, about 19% below Tuesday’s closing price of $3.09. Esperion expects to raise roughly $75 million from the sale of 30 million shares, with an option for underwriters to buy an additional 4.5 million shares over the next month. The deal is expected to close around Oct. 9.Meanwhile, Morgan Stanley, Piper Sandler, and Cantor Fitzgerald are leading the offering, joined by Citizens JMP Securities, H.C. Wainwright, and Needham &amp; Company as co-managers. Esperion said the proceeds will go toward expanding commercialization of its non-statin cholesterol treatments and strengthening its financial position.The fundraising effort comes after the Michigan-based biotech firm notched a legal win protecting its core cholesterol-lowering drugs. Last week,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/esperion-shares-rally-after-patent-litigation-settlement-for-cholestrol-drugs/chCujWhR3Qb">Esperion reached a settlement with Dr. Reddy’s Laboratories</a>, ensuring the Indian pharma company cannot market generic versions of Nexletol and Nexlizet in the U.S. before April 19, 2040.That settlement followed similar agreements with Micro Labs USA, Hetero USA, and Accord Healthcare, effectively shoring up Esperion’s patent on bempedoic acid, the key ingredient in both drugs, through December 2030.On Stocktwits, retail sentiment for Esperion was ‘bullish’ amid ‘high’ message volume.One retail trader said the real question now is whether Esperion will use the new funds wisely, whether to repay debt and support its late-stage trials, rather than chase new acquisitions or side projects, which could signal poor capital discipline.<stembedurl>https://stocktwits.com/Sirius1026/message/631430171</stembedurl>Another user speculated that the timing of the offering hinted at deeper management motives, suggesting the cash crunch might be over and predicting a quick rebound above $3.<stembedurl>https://stocktwits.com/Rescueoncredit/message/631430163</stembedurl><a href="https://stocktwits.com/symbol/ESPR">Esperion’s stock</a> has risen 40.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Why Is Esperion Therapeutics Stock Sinking Premarket Today?

The stock fell sharply in early trade after the cholesterol drugmaker priced its latest stock sale at a discount to Tuesday’s close.

Equity

ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up

Esperion settles Nexletol and Nexlizet patent dispute with Dr. Reddy's, securing U.S. market exclusivity until 2040 and lifting its shares nearly 14%.

Esperion (ESPR) on Friday said that it has entered into a settlement agreement with Dr. Reddy’s Laboratories and its affiliate under which the latter has agreed not to market a generic version of either Nexletol or Nexlizet in the United States before April 19, 2040.The agreement <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/03/3160929/0/en/Esperion-Reaches-Settlement-Agreement-with-ANDA-Filer-Dr-Reddy-s-Laboratories-Not-to-Market-Generic-Versions-of-NEXLETOL-bempedoic-acid-and-NEXLIZET-bempedoic-acid-and-ezetimibe-Pr.html">resolves</a> the patent litigation brought by Esperion against Dr. Reddy’s Laboratories after it submitted an Abbreviated New Drug Application seeking approval to market a generic version of each of Nexletol and Nexlizet.The two drugs are used to reduce low-density lipoprotein (LDL) or "bad" cholesterol in adults with high blood cholesterol levels, known as primary hyperlipidemia. Shares of Esperion traded 8% higher in the pre-market session at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ESPR">ESPR stock</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.Esperion reached a settlement agreement with Micro Labs USA and its affiliate; Hetero USA, and its affiliates; and Accord Healthcare earlier this year with respect to their generic versions of Nexletol.The bempedoic acid portion of the two drugs is claimed in an Esperion patent scheduled to expire in December 2030, the company said. With the settlement with Dr. Reddy’s, there are no remaining challenges regarding the validity or infringement of the said patent in the pending patent litigation, it added.The company also stated that there is no assurance that the ongoing patent litigation against the remaining defendants, including Alkem Laboratories, will allow a generic version of the cholesterol drugs to be marketed in the U.S. before April 19, 2040.ESPR stock is up by 32% this year and by approximately 48% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ovid-therapeutics-stock-rally-pre-market-after-positive-results-from-trial-of-potential-seizure-treatment/chCuj8HR3Q2">Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Esperion Shares Rally After Patent Litigation Settlement For Cholesterol Drugs

The company said that Dr. Reddy’s Laboratories has agreed not to market a generic version of either Nexletol or Nexlizet in the U.S. before April 19, 2040. 

Are Options Traders Betting on a Big Move in Esperion Therapeutics Stock?

Investors need to pay close attention to Esperion Therapeutics stock based on the movements in the options market lately.

ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises

Esperion posts narrower-than-expected second-quarter loss with revenues rising 12% and product sales jumping 42% year over year.

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of +88.24% and +24.28%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline

CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of +8.16% and +5.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Esperion Therapeutics Inc.

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$2.65
Prev Close	$2.52
Open	$2.53
Dividend Yield	0.00%
50-Day Moving Average	$2.45
Beta	0.91
Avg. Volume	7.05M
PE Ratio	-4.74

52-Week High	$3.94
52-Week Low	$0.6925
Market Capitalization	$583.69M
EPS (Annual)	-$0.2764
Price to Book	-1.16
Revenue Per Employee	$1.09M
Enterprise Value/EBITDA	N/A

ESPR
Esperion Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ESPR News

ESPREsperion Therapeutics Inc.